ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis

This study is currently recruiting participants.
Verified by Ophthalmic Consultants of Long Island, December 2006

Sponsors and Collaborators: Ophthalmic Consultants of Long Island
Bausch & Lomb, Inc.
Information provided by: Ophthalmic Consultants of Long Island
ClinicalTrials.gov Identifier: NCT00407043
  Purpose

To evaluate the impact of Lotemax on the initiation of Restasis therapy in patients with dry eye.

It is hypothesized that the anti-inflammatory activity of Lotemax may help mitigate the stinging with cyclosporine administration and the dry eye signs and symptoms experienced during the initiation of therapy.


Condition Intervention Phase
Dry Eye Disease
Keratoconjunctivitis Sicca
Drug: Lotemax
Drug: Restasis
Phase IV

MedlinePlus related topics:   Eye Diseases   

ChemIDplus related topics:   Cyclosporine    Cyclosporin    Loteprednol    Loteprednol etabonate   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title:   A Prospective, Multicenter, Randomized Controlled Study of the Effect of Lotepredol Etabonate on The Initiation of Dry Eye Treatment With Topical Cyclosporine

Further study details as provided by Ophthalmic Consultants of Long Island:

Primary Outcome Measures:
  • Ocular Surface Disease Questionnnaire Results
  • Lissamine green staining
  • Fluorescein Staining
  • Schirmer testing

Estimated Enrollment:   120
Study Start Date:   November 2006
Estimated Study Completion Date:   November 2006

Detailed Description:

Dry eye is an ocular surface disease that produces discomfort and irritation. Estimated prevalence ranges from 20 million people in the US being affected with mild to moderate dry eye, to as many as one out of every five Americans.

A growing body of evidence has associated ocular inflammation with the signs and symptoms of dry eye.

Restasis is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with a condition called keratoconjunctivitis sicca. The relief of dry eye signs and symptoms with Restasis therapy is often delayed by 1 to 6 months from the initiation of therapy. Stinging on installation, particularly when initiating therapy, has been reported.

Lotemax, an ophthalmic corticosteroid, targets inflammation with a unique, site-active mechanism of action.Structural modifications associated with an ester ophthalmic steroid make Lotemax highly lipid soluble, enhancing penetration into cells and enabling Lotemax to exert anti-inflammatory activity within the eye. Lotemax is indicated for the treatment of steroid responsive inflammatory conditions associated with the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.

  Eligibility
Ages Eligible for Study:   30 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion Criteria:

  • Between the ages of 30 and 80 inclusive.
  • Has not worn contact lenses for at least 1 month prior to the study and agrees to not wear contact lenses during study.
  • Oral medications stable 1 month prior to study.
  • Oral medications anticipated to be stable during 60 day study.
  • Patient is in generally good & stable overall health.
  • Patient likely to comply with eye drop regimen, study guidelines & study visits.
  • Corneal stain > 1+ or Conjunctival stain > 1+ or OSDI equal or > 5 or using regular artificial tears at least on average twice daily.
  • Informed consent signed.

Exclusion Criteria:

  • History of Stevens-Johnson Syndrome or Ocular Pemphigoid.
  • Punctal plugs inserted or punctal cautery in the past 3 months.
  • Intra-ocular surgery within 6 months or ocular laser surgery within 3 months.
  • History of liver disease.
  • Pregnant or lactating women.
  • Severe clinical vitamin deficiencies or history of vitamin overdose.
  • Highly variable vitamin intake.
  • Unstable use of systemic or topical medications known to create dry eye.
  • Corneal pathology, which could, of itself, cause an ocular surface disorder.
  • Use of glaucoma medications, topical or oral.
  • Unstable diabetes mellitus.
  • Allergy or sensitivity to Lotemax, Restasis or the OTC Tear Supplement.
  • Use of topical steroids or Restasis within the past 1 month.
  • Use of other topical ocular agents other than tear replacements within the past 1 week.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00407043

Contacts
Contact: Eric Donnenfeld, MD     516-766-2519     eddoph@aol.com    

Locations
United States, New York
Ophthalmic Consultants of Long Island     Recruiting
      Lynbrook, New York, United States, 11563
      Principal Investigator: Eric Donnenfeld, MD            

Sponsors and Collaborators
Ophthalmic Consultants of Long Island
Bausch & Lomb, Inc.

Investigators
Study Director:     Maria Howard     Ophthalmic Consultants of Long Island    
  More Information

Study ID Numbers:   Donnenfeld Review 1
First Received:   November 30, 2006
Last Updated:   December 4, 2006
ClinicalTrials.gov Identifier:   NCT00407043
Health Authority:   United States: Institutional Review Board

Keywords provided by Ophthalmic Consultants of Long Island:
Dry Eye Disease  
Lotemax  
Restasis  
Loteprednol  
Cyclosporine  

Study placed in the following topic categories:
Corneal Diseases
Cyclosporine
Clotrimazole
Keratoconjunctivitis sicca
Miconazole
Eye Diseases
Tioconazole
Lacrimal Apparatus Diseases
Dry Eye Syndromes
Conjunctivitis
Cyclosporins
Keratoconjunctivitis
Loteprednol etabonate
Conjunctival Diseases
Xerophthalmia
Keratitis
Keratoconjunctivitis Sicca

Additional relevant MeSH terms:
Anti-Infective Agents
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Antifungal Agents
Physiological Effects of Drugs
Enzyme Inhibitors
Anti-Allergic Agents
Antirheumatic Agents
Dermatologic Agents
Immunosuppressive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 20, 2008




Links to all studies - primarily for crawlers